RCEL / AVITA Medical Inc. (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript

The FDA is asking for more information regarding Avita's Recell Go device. The Recell Go is a more automated version of an already approved product fo more_horizontal

VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the develop more_horizontal

VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the develop more_horizontal

AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relatio more_horizontal

AVITA Medical: Innovative device to treat skin injuries gaining sales momentum. Recent FDA approvals of full-thickness skin defects and Vitiligo great more_horizontal

Avita Medical Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might no more_horizontal

Avita specializes in devices and therapies to restore skin growth. The FDA's nod means that the company's Recell system can expand beyond applications more_horizontal

AVITA (RCEL) surges on FDA approval for expanded use of its RECELL System to treat full-thickness skin defects. more_horizontal